The identification of pharmacodynamic biomarkers involves several steps, starting with preclinical studies in cell lines and animal models. These findings are then validated in clinical trials involving cancer patients. Techniques such as genomics, proteomics, and metabolomics are commonly used to identify and validate these biomarkers.
